Tag:
macular degeneration
Latest Headlines
Latest Headlines
Glaucoma-stricken rats see better, thanks to stem cells
Researchers at University College London have successfully used human eye stem cells to repair glaucoma damage in rats.
Hungry Valeant snags Eyetech in ongoing buyout spree
Valeant Pharmaceuticals today continued its restless buyout spree, snapping up Eyetech , a small FL-based company that sells the anti-VEGF pioneer Macugen in the U.S. And while Valeant ( $VRX ) didn't
ACT trumpets positive efficacy data from ESC trial sampling
The beleaguered embryonic stem cell field got a boost today from a clinical trial sample in which two legally blind patients demonstrated partially restored vision after getting an injection of new
Vitamin D helps (more than) 3 (nearly) blind mice see
Somewhere in the U.K., lots of older mice can see better, thanks, apparently, to a 6-week dose of vitamin D. Researchers at the Institute of Ophthalmology at University College London found those
Genentech pursues sustained-delivery version of blockbuster eye drug Lucentis
Ah, progress. Genentech has overcome an initial hurtle in its push to develop a sustained-delivery version of Lucentis , the company's blockbuster drug for age-related macular degeneration. The...
Nanoparticles carting steroids to retina delay macular degeneration
Researchers have developed a sustained-release drug delivery system that successfully brought steroids to the retina to treat degenerative eye conditions. Nanoparticles known as dendrimers gave the
Regeneron finally captures an FDA OK with new eye drug
Late on Friday Regeneron Pharmaceuticals ( $REGN ) scored a big win as it announced that the FDA has approved Eylea (aflibercept) for wet, age-related macular degeneration. But after pricing an
Eyetech vets launch Imagen Biotech with $40M A round
SV Life Sciences , Novo Ventures and Fidelity Biosciences joined forces to launch a new drug developer, Imagen Biotech, with "up to" $40 million in venture bucks to finance new work on treatments for
Following up on great expectations for stem cell clinical trials
Time Magazine follows up on Advanced Cell Technology's upcoming clinical trials for embryonic stem cell treatments for macular degeneration and dystrophy by finding a participant, a 26-year-old woman
Advanced Cell Technology to begin stem cell trials for eye diseases
Advanced Cell Technology has spent the last decade working on an embryonic stem cell treatment for eye diseases and that work is about to undergo its first big test in July when trials begin in
